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Introduction 
Tryptophan is one of the essential amino acids used for protein biosynthesis. 
The degradation of tryptophan can lead to the formation of serotonin, a 
monoamine neurotransmitter known as a regulator in the limbic system. 
However, the serotonin pathway comprises only a small portion of the 
tryptophan catabolism, since 99% of the tryptophan is catabolized through 
the kynurenine pathway. It is a cascade of enzymatic steps generating 
biologically active compounds. 
 In this pathway L-Kynurenine (L-KYN) is a central metabolite. The early 
phase of the catabolic steps takes place mainly in the liver and the kidneys. 
However, the metabolization of L-KYN can effectively proceeds in the 
brain. The blood brain barrier strongly limits the penetrability of the 
kynurenine metabolites from the periphery to the central nervous system, 
since most of them can only be transferred by passive diffusion with a very 
low efficacy.  One clear exception is the L-KYN, which can enter the brain 
with the aid of a large neutral amino acid transporter. Thus, the cerebral 
kynurenine metabolism is very responsive to the peripheral level of the 
L-KYN. Preclinical studies have shown that growth in the level of systemic 
L-KYN is particularly associated with a dose-dependent increase of its direct 
downstream metabolite kynurenic acid (KYNA) in the central nervous 
system. Evidence suggests that in the physiologically intact brain the most 
prominent and rapid change after peripheral L-KYN administration is the 
peak elevation of KYNA. 
KYNA is a complex neuromodulator, antioxidant and neuroprotective 
endogenous molecule.  Elevation of brain KYNA content is correlated with 
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attenuation in the concentration of extracellular glutamate, dopamine and 
acetylcholine in distinct cortical and subcortical brain regions. KYNA 
influences neurotransmission through multiple actions at the pre- and 
postsynaptic site. KYNA directly attenuates neurotransmitter release, partly 
by inhibiting α7 nicotinic acetylcholine (α7nACh) receptor located on 
presynaptic terminals, and partly by stimulating G-protein-coupled receptor 
35 (GPR35) localized on neurons and astrocytes. Thus, even the modest 
fluctuations in endogenous KYNA can bi-directionally control the 
extracellular levels of glutamate. KYNA hinders postsynaptic 
N-methyl-D-aspartate (NMDA) receptor currents by competitive 
antagonism at allosteric glycine binding site of NMDA receptor. Moreover, 
in the periphery and in the brain during neuroinflammation, KYNA promotes 
anti-inflammatory responses due to activation of aryl hydrocarbon receptor 
and GPR35 receptor expressed by immune-cells, as well as it presumably 
also modulates neuronal survival through extrasynaptic NMDA receptor 
blockade. Besides its receptor-mediated actions, KYNA itself is a potent 
antioxidant.  
Therefore, elevation of brain KYNA level, either by administration of 
L-KYN or pharmacological manipulation of the availability of the 
kynurenine pathway enzymes, has become an attractive strategy to attenuate 
neuroinflammatory responses and to protect against glutamate induced 
excitotoxicity associated with ischemic brain injury. Accordingly, we and 
our collaborators achieved neuroprotection by the administration of L-KYN 
sulfate (L-KYNs) in experimental models of neurodegenerative diseases and 
ischemic stroke. Decades after the discovery of the neurotoxic and 
convulsant properties of glutamate, it has become clear that glutamate 
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hypofunction is also pathogenic and therefore undesirable. Accordingly, in 
preclinical studies acute or chronic elevation of brain KYNA content, 
achieved partly by the peripheral administration of L-KYN, has been 
suggested to trigger alteration in the behavior of rodents: animals expressed 
hypoactivity or spatial working memory deficit. Moreover, pre- and 
postnatal chronic L-KYN exposure provoked long-lasting neurochemical 
and behavioral abnormalities manifested in adulthood. However, the results 
assessing the behavioral effects of the kynurenerg manipulations emerged 
from studies that focused mainly on rats, after various-dose of L-KYNs 
treatment. Implementing similar experiments in mice is of particular 
importance, because such data is almost absent from the literature. 
Additionally, the available information concerning the effects of kynurenerg 
manipulation beyond neuroprotection is quite incomplete, since study on 
dose-dependent responses to various L-KYNs treatment is not available.  
On a top of these, L-KYN and KYNA were attributed a direct role in the 
regulation of the systemic circulation. Namely, L-KYN was identified as an 
endothelium-derived vasodilator, contributing to peripheral arterial 
relaxation and regulation of blood pressure during systemic inflammation in 
rats. Furthermore, intravenous administration of low-dose L-KYN (1 mg/kg) 
has been shown to increase cerebral blood flow (CBF) in conscious rabbits. 
Therefore, we hypothesized that acute elevation of systemic L-KYN 
concentration may exert potential effects on mean arterial blood pressure 
(MABP) and on resting CBF in the adult mouse brain. 
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Aims 
The experimental work of my thesis can be arranged to three main parts. Our 
specific research interests focused on the physiological intact C57Bl/6j mice, 
with the following questions: 
1. How will the various L-KYNs treatments influence the locomotion 
activity, the episodic-like memory formation and the anxiety-like 
behaviors?   
2. Does the L-KYNs treatment interferes with the neuronal activity of 
brain structures relevant to the behavioral experiments that can be 
visualized by means of immunohistochemical technique?  
3. Does a high-dose L-KYNs treatment influences the systemic blood 
pressure or the cerebral blood flow anyhow? 
Methods 
For the experiments 8 – 12 weeks old adult male C57Bl/6j mice (n = 216, 
body weight 28 ± 3 g) were used, which were housed under controlled 
laboratory conditions. All housing and experiments were conducted in 
accordance with the European Communities Council Directives 
(86/609/ECC) and the Hungarian Act for the Protection of Animals in 
Research (XXVIII.tv. 32.§). Efforts were made to minimize the number of 
animals used and to reduce pain and discomfort. All of the experiments were 
approved by the following ethical license: XX/01593/I/2010. 
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1. Behavioral tests 
In the first set of experiments, we wanted to assess the acute effects of 
L-KYNs treatment on the behavior of the animals, thus the mice were 
administered a various dose of L-KYNs (25 mg/bwkg, 50 mg/bwkg, 
100 mg/bwkg, 200 mg/bwkg, 300 mg/bwkg) intraperitoneally 2 h before the 
experiments. The mice of control group were injected with the vehicle 
(0.1M phosphate buffer; pH 7.4). Experiments were video tracked by a 
coloured CCD camera (Sony, model: SSC-DC378P) connected to a personal 
computer. Behavioral data were collected and analyzed automatically with 
the SMART video-tracking system (PanLAB) or scored manually. 
The ambulatory activity was assessed in an open field (OF) paradigm. The 
OF consisted of a square arena (50 × 50 cm) enclosed by continuous, 
50-cm-high, light-gray opaque walls made of plexiglass. The animals were 
allowed to move freely for 8 min, while their horizontal ambulatory activity 
was tracked with the aid of a video-tracking system (SMART® by Panlab 
Harvard Apparatus). This allowed us to measure all the required parameters: 
total distance moved (cm), percentage of time spent immobility (%), average 
speed (cm/s). 
Episodic-like memory performance was tested in a novel object recognition 
(NOR) paradigm. During this test the animals have to distinguish between a 
previously seen familiar object and a novel object. In order to analyze the 
NOR performance of the mice, a discrimination index (DI) was calculated as 
follows: novel × 100/(novel + familiar), where “novel” is the time spent 
exploring a novel object and “familiar” is the time spent exploring a familiar 
one. This shows the object exploration preference, expressed in percentage. 
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Anxiety-like behavior was evaluated in an elevated plus-maze (EPM) 
paradigm. The nocturnal rodents instinctively avoid strongly illuminated 
open spaces. The EPM contains enclosed and open arms illuminated 
differently. Thus, the risk-bearing capability of the animals can be measured 
by quantifying the proportion of time spent in the open arms. 
2. Histology 
In order to study possible alterations in neural activity caused by an acute 
high-dose of L-KYNs administration (300 mg/bwkg) we measured changes 
of basal c-Fos expression in brain structures relevant to the behavioral 
experiments. Thus we performed c-Fos immunostaining in the CA1 area of 
the hippocampus and in the dorsal part of the striatum in the mice. First, we 
obtained 20-µm-thick coronal sections from the paraformaldehyde (4%) 
fixed mice brain (+0.54 mm and –2 mm from the bregma). In order to detect 
c-Fos-positive neurons in the striatum and in the hippocampus, sections were 
labeled by fluorescent immunohistochemical method. Then, fluorescent 
photomicrographs were obtained with an Olympus BX51microscope fitted 
with a DP70 digital imaging system. In both areas a subregion was delineated 
manually for the analyzation. Then c-Fos+ cells were automatically counted 
with custom-written software in MATLAB 7.1 (Mathworks, Natick, 
Massachusetts, USA). After automated threshold adjustment and noise 
reduction, fluorescent objects in the range 25–400 µm2 were accepted as 
cells and counted in binary images. 
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3. Mean arterial blood pressure (MABP) and cerebral blood 
flow (CBF) measurements 
In the last set of experiment, we set out to obtain comparable information 
about the potential vascular effects of high-dose L-KYNs administration 
(300 mg/bwkg). On the day of experiments, the animals were anesthetized 
with isoflurane (1.5% induction, 1% maintenance in N2O:O2, 70:30%) and 
allowed to breath spontaneously through a head mask. The left femoral artery 
was cannulated for the continuous acquisition of MABP. While CBF was 
assessed through the intact parietal bone with the aid of laser speckle contrast 
imaging (PeriCamPSI HR System®, Perimed, Järfälla, Sweden). All 
variables were simultaneously acquired and stored using a personal computer 
with dedicated softwares (PeriSoft 2.5.5 for BP and PimSoft 1.5.4.8 for CBF 
Perimed, Järfälla, Sweden). Data analysis was conducted by custom written 
scripts in a MATlab environment (MathWorks Inc., MA, USA). After taking 
a baseline of 20 min registration, a single injection of L-KYNs or vehicle of 
the same volume (0.2ml) was administered intraperitoneally. Subsequently, 
MABP and CBF were continuously monitored for at least 2.5 h. To 
determine the changes in CBF, identical regions of interest were positioned 
over each hemisphere, over the somatosensory cortical area. The size of this 
area was 2.5 ± 0.3 mm2. Raw CBF changes were expressed relative to 
baseline by using the average CBF value of the first 5 min of registration 
(100%) and the recorded biological zero obtained after terminating the 
animal (0%) as reference points. In order to discriminate significant CBF 
variations reliably, a range of normal CBF variation was determined 
according to a threshold level (±1.5 stdev) for each individual measurement. 
Consequently, when CBF dropped below the determined threshold range, a 
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cerebral hypoperfusion transient, when exceeded that, a cerebral hyperemic 
transient was noted and the events were taken for further quantitative 
analysis. The following elements of the CBF transients were characterized: 
peak amplitude (%), duration (s), and magnitude expressed as area under the 
curve (% * s). 
Results and discussion 
1. Behavioral effects 
Locomotion activity (OF) 
The average speed of the control animals was 9.58 ± 1.1 cm/s, and they spent 
28 ± 10% of the time without horizontal moving activity (immobility). 
Consequently, their total distance passed was 3390 ± 630 cm. Since the 
measured parameters of the various control groups were differed slightly 
from each other, every L-KYNs treated group was compared to a control 
group assigned on the same day (n = 9 – 10/group). The analyzation of the 
groups treated with lower-dose of L-KYNs (25 mg/bwkg, 50 mg/bwkg) 
confirms no statistical difference in any of the measured parameters. A 
One-Way MANOVA revealed a significant multivariate main effect for the 
treatment of 100 mg/bwkg L-KYNs (Pillai’s trace = 0.419, F(3, 14) = 3.372 , 
p = 0.049). The animals moved slower, spent more time in immobility, so 
the total distance moved was decreased. Interestingly an opposite behavioral 
pattern emerged as a result of a higher dose of treatment. The administration 
of 200 mg/bwkg or 300 mg/bwkg L-KYNs significantly elevated movement 
velocity of the mice as compared with the vehicle-treated groups. Activation 
was observed mainly in their average speed, while their immobility time did 
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not decrease. In summary the mice expressed hypoactivity owing to a 
lower-dose of L-KYNs treatment, whereas the animals become hyperactive 
as the dose was raised over 100 mg/bwkg. The most prominent locomotor 
disturbances were seen in the 300 mg/bwkg treated group. Our results fit in 
the literature. It was shown previously that moderate dose of L-KYNs 
treatment (100 mg/bwkg) hinders the voluntary ambulatory activity of rats. 
The effects of a high dose of L-KYNs on the movement velocity was not 
investigated previously, so our findings are completely new. However, 
similar behavioral observations were reported earlier following systemic 
administration of the non-competitive NMDA receptor antagonist MK-801 
to C57Bl/6 mice; the injection of a relatively low dose of MK-801 disrupted 
the movement velocity controls inducing an abnormal hyperactive condition. 
On the one hand we could verify that moderate L-KYNs treatment hinders 
the locomotor activity of mice just as it was reported in rats. On the other 
hand, our data revealed that a high dose of L-KYNs treatment impairs further 
the controls of voluntary movement by inducing an irregular hyperactive 
state, which can be correlated at least partly with the blockade of NMDA 
receptors. Therefore, we uncovered a non-linear dose-dependent 
characteristic of the L-KYNs treatment on the locomotion activity of mice. 
Episodic-like memory performance (NOR) 
In the vehicle-treated and the 25 mg/bwkg treated group mice spent more 
time exploring the novel object. In contrast the higher-dose L-KYNs-treated 
groups (100 mg/bwkg, 300 mg/bwkg) failed to recognize the novel object 
and spent equal times exploring both objects. As a result, the 100 mg/bwkg 
and 300 mg/bwkg treated mice object recognition memory performance was 
significantly hindered, expressed as DIs (63 ± 12.6%, 61.8±15.9%, 
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47.1 ± 10.7%, 48.1 ± 12.8%; vehicle, 25 mg/bwkg, 100 mg/bwkg, 
300 mg/bwkg L-KYNs) (n = 10-12/group). Accordingly, we can assume that 
the elevated brain KYNA content owing to a moderate to high dose of 
L-KYNs treatment interfered with the formation of recollection of the 
familiar object (encoding and memory consolidation). Thus it led to the 
impaired NOR memory performance. Others observed similar results after 
kynurenergic manipulation. In a radial arm maze paradigm systemic 
L-KYNs treatment (100 mg/bwkg) impaired the spatial working memory 
function in rats. Our data reinforce the amnestic property of the kynurenergic 
manipulation and confirms this effect in mice. Besides we may complete this 
notion with the following: under moderate dose of L-KYN (100 mg/bwkg) 
treatment significant memory disruption may not evolve.  
Anxiety-like behavior (EPM) 
The control animals entered the well-lit open arms of the EPM 12 ± 3 times 
on average, and spent 15 ± 7% of the time (300 s) exploring it. The ratio of 
the open-arm exploration was elevated dose-dependently (15 ± 7%, 
23 ± 17%, 23 ± 12%, 25 ± 6%; vehicle, 25 mg/bwkg, 100 mg/bwkg, 
300 mg/bwkg L-KYNs), while the ratio of the enclosed-arm exploration was 
diminished (75 ± 8%, 61 ± 21%, 60 ± 19%, 58 ± 7%; vehicle, 25 mg/bwkg, 
100 mg/bwkg, 300 mg/bwkg L-KYNs) (n = 10-12/group). However, only 
the 300 mg/bwkg treated group differed statistically from the control group. 
Based on these findings we may conclude that the treatment increased the 
risk-taking behavior of the animals. In a similar set of experiments done by 
others an acute anxiolytic effect of the systemic L-KYN treatment was 
challenged. However, significant influence cannot be revealed in rats. 
Conversely we could demonstrate that the mice spent significantly more time 
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in the aversive open spaces of the platform. Consequently, the treatment 
dose-dependent anxiolytic effect was revealed. 
2. Histological results 
In a separate group of animals we estimated c-Fos expression levels in brain 
areas corresponding to behavioral paradigm following a systemic 
administration of a high dose of L-KYNs (300 mg/bwkg) (n = 10/group) 
administration. The dose was chosen based on a previous set of experiments. 
In the control group strong c-Fos immunopositivity was observed in the 
medial part of the dorsal striatum, whereas high number of cells expressing 
the c-Fos protein in the analyzed subsection (485 ± 245). A similar tendency 
was observed in the CA1 pyramidal cell layer (56 ± 22). In the 
L-KYNs-treated group, cells expressing the c-Fos protein were sporadic and 
their number were lower in the dorsal striatum (220 ± 121) and the 
hippocampus (32 ± 21) compared to the vehicle-treated group. In rodents the 
functional integrity of hippocampal CA1 region is essential to the formation 
of object recognition memory. There is an unequivocal relationship between 
decreased hippocampal c-Fos expression and episodic-memory 
impairments. Striatal medium-sized spiny neurons are one of the central 
components of the sensorimotor cortico-basal ganglia network, which is 
responsible for controlling voluntary movements and plays a critical role in 
determining the movement speed. The relationship between the dorsal 
striatum activity and c-Fos expression is well-described. In our experiment a 
high-dose of L-KYNs treatment (300 mg/bwkg) decreases the number of 
c-Fos-immunopositive-cells in both areas. Thus our data revealed that 
behavioral abnormalities owing to a single exposure of high-dose L-KYNs 
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may emerges related to the altered basal c-Fos protein expression and the 
imbalance of the striatal and hippocampal neuronal activity. 
3. Circulatory effects 
In the control group, MABP and CBF were stable (69 ± 4 mmHg and 100 ± 
5%, respectively) throughout the entire data acquisition period. In the 
L-KYNs-treated group, MABP was similar to that, of control group (73 ± 
6 mmHg), while hypoperfusion transients of 22 ± 6%, lasting 7 ± 3 min 
occurred in the cerebral cortex over the first 60 – 120 min following drug 
administration (n = 8/group). Here we have shown that the L-KYNs 
treatment destabilized resting CBF of isoflurane-anesthetized mice by 
inducing a number of transient hypoperfusion events, with no simultaneous 
influence on MABP. The present data are at variance with previous 
observations attributing a vasodilator and blood pressure lowering effect to 
L-KYN, which may be due to the various L-KYN concentrations used, or 
the induction or lack of anesthesia, or species difference. While the exact 
molecular mechanism leading from elevated level of KYNA to vascular 
diameter changes remain to be clarified. Clearly, a number of possible 
processes could be operative in our model. One explanation could be that 
KYNA hinders the tonic activity of cortical astrocytes through non-neuronal, 
Mg2+-insensitive NMDA receptor and GPR35 receptor. KYNA action on 
both receptor types leads to attenuated intracellular Ca2+ levels, associated 
with hindered release of vasoactive arachidonic acid substance and impaired 
control of CBF. Thus, this astrocytic pathway could be implicated in the 
cerebral hypoperfusion transients in response to high dose L-KYNs 
administration. The CBF attenuating property of L-KYN or KYNA is 
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completely novel finding. Although, up to this point the possibility that this 
manipulation might interfere with the cerebrovascular regulation was not 
taken into account. 
Summary 
The impairment of the kynurenine pathway metabolism is increasingly 
considered to be involved in the occurrence and the progression of 
neurophysiological dysfunctions observed in various neurodegenerative 
diseases. Thus, manipulation of the availability of kynurenine metabolites 
with the aim of therapy has been extensively investigated recently. 
Although, up to this point a detailed dose-response study related to the 
kynurenine manipulation effects beyond neuroprotection was not done. 
We have demonstrated that a single moderate L-KYNs administration 
can provoke numerous behavioral disturbances, whereas these effects 
become more dominant with the increase of L-KYNs concentration. 
Therefore, a single high-dose L-KYNs treatment next to the behavioral 
influences, could also alter genexpression and destabilizes resting CBF, 
a phenomenon that should be considered by interpreting the effect of 
kynurenergic manipulation on brain function. By planning clinical trials 
basing on kynurenergic manipulation possible behavioral and vascular 
side effects should also be considered. 
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